Plasma-derived exosomal human epidermal growth factor receptor 2 (HER2) protein for distinguishing breast cancer from benign breast disease and assessing the efficacy of neoadjuvant therapy
Plasma-derived exosomal HER2 might serve as a promising biomarker for distinguishing breast cancer from benign breast disease, screening patients who could benefit from HER2-targeted therapy, and monitoring neoadjuvant therapy.
Authors
- Yu Xia
- Chunmiao Han (ORCID: https://orcid.org/0000-0002-6383-8287)
- Jinwen Qu
- Zhaofen Ba
- Xiaofang Yang (ORCID: https://orcid.org/0000-0003-4464-7925)
- Rong Wang (ORCID: https://orcid.org/0000-0003-3502-5446)
- Yibin Wang (ORCID: https://orcid.org/0000-0003-0852-0767)
- Jing Lan (ORCID: https://orcid.org/0000-0001-8313-6795)
- Yipu Wang (ORCID: https://orcid.org/0009-0006-2137-2075)
- Mengdan Xu (ORCID: https://orcid.org/0000-0001-9347-0770)
- Yehui Zhou
Institutions
- Soochow University (CN)
- First Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- Translational Cancer Research
- Published
- 2025-05-01
- DOI
- https://doi.org/10.21037/tcr-2025-825
- Citations
- 4
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 5.44